The interest in the application of new drugs, materials, and other bioactive compounds, as well as the introduction of new methods in various medical disciplines, is not usually accompanied by the need for the estimation of adverse effects of such therapeutic approaches in a broad field of clinically targeted pathologies. Numerous data confirmed toxicities of new protocols in various organs and tissues, including neurotoxicity. Since neurotoxicity may be considered as both the earliest sign and principle limiting factor in different therapeutic approaches in medical trials, it requires further elucidation of its general mechanisms, in order to compromise the efficiency and safety of bioactive materials employed in medicine.
Although neurotoxicity is usually considered one of the most frequent adverse effects in various therapeutic protocols, it seems that more attention is focused on other side effects (hepatotoxicity, nephrotoxicity, etc.), so the varieties of manifestations of neurotoxicity are often concealed, and consequently untreated. For that reason, this research topic intends to provide an integrated view of current and novel research on the basic mechanisms underlying iatrogenic neurotoxicity. The aim of this research topic is to allow a comprehensive insight based on both original research and review articles that focus on iatrogenic neurotoxicity.
All article types accepted by the Journal are welcome. We are looking forward to promoting submissions focusing either on the results obtained in preclinical studies or in clinical trials. Sub-topics of interest include:
• Behavioral manifestations of iatrogenic neurotoxicity.
• Pharmacological approaches in treatment of iatrogenic neurotoxicity.
• Iatrogenic peripheral neuropathy.
• Cancer treatment and neurotoxicity.
• COVID-19 and neurotoxicity.
• Antioxidants in treatment of iatrogenic neurotoxicity.
• Natural products in treatment of iatrogenic neurotoxicity.
• Pollution and neurotoxicity.
• Nanoparticles-induced neurotoxicity.
• Nanoparticles in treatment of iatrogenic neurotoxicity.
The interest in the application of new drugs, materials, and other bioactive compounds, as well as the introduction of new methods in various medical disciplines, is not usually accompanied by the need for the estimation of adverse effects of such therapeutic approaches in a broad field of clinically targeted pathologies. Numerous data confirmed toxicities of new protocols in various organs and tissues, including neurotoxicity. Since neurotoxicity may be considered as both the earliest sign and principle limiting factor in different therapeutic approaches in medical trials, it requires further elucidation of its general mechanisms, in order to compromise the efficiency and safety of bioactive materials employed in medicine.
Although neurotoxicity is usually considered one of the most frequent adverse effects in various therapeutic protocols, it seems that more attention is focused on other side effects (hepatotoxicity, nephrotoxicity, etc.), so the varieties of manifestations of neurotoxicity are often concealed, and consequently untreated. For that reason, this research topic intends to provide an integrated view of current and novel research on the basic mechanisms underlying iatrogenic neurotoxicity. The aim of this research topic is to allow a comprehensive insight based on both original research and review articles that focus on iatrogenic neurotoxicity.
All article types accepted by the Journal are welcome. We are looking forward to promoting submissions focusing either on the results obtained in preclinical studies or in clinical trials. Sub-topics of interest include:
• Behavioral manifestations of iatrogenic neurotoxicity.
• Pharmacological approaches in treatment of iatrogenic neurotoxicity.
• Iatrogenic peripheral neuropathy.
• Cancer treatment and neurotoxicity.
• COVID-19 and neurotoxicity.
• Antioxidants in treatment of iatrogenic neurotoxicity.
• Natural products in treatment of iatrogenic neurotoxicity.
• Pollution and neurotoxicity.
• Nanoparticles-induced neurotoxicity.
• Nanoparticles in treatment of iatrogenic neurotoxicity.
